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Objectives The aim of this study was to investigate the effect of renin-angiotensin system blockade on outcomes in patients
with aortic regurgitation (AR).
Background Angiotensin-converting enzyme (ACE) inhibitors have the potential to reduce afterload, blunt left ventricular wall
stress, and limit left ventricular dilation and hypertrophy. However, long-term studies have yielded inconsistent
results, and very few have assessed clinical outcomes.
Methods The Health Informatics Centre dispensed prescription and morbidity and mortality database for the population of
Tayside, Scotland, was linked through a unique patient identifier to the Tayside echocardiography database. Pa-
tients diagnosed with at least moderate AR from 1993 to 2008 were identified. Cox regression analysis was
used to assess differences in all-cause mortality and cardiovascular (CV) and AR events (heart failure hospitaliza-
tions, heart failure deaths, or aortic valve replacement) between those treated with and without ACE inhibitors or
angiotensin receptor blockers (ARBs).
Results A total of 2,266 subjects with AR (median age 74 years; interquartile range: 64 to 81 years) were studied, with
a mean follow-up period of 4.4  3.7 years. Seven hundred and five patients (31%) received ACE inhibitor or
ARB therapy. There were 582 all-cause deaths (25.7%). Patients treated with ACE inhibitors or ARBs had signifi-
cantly lower all-cause mortality and fewer CV and AR events, with adjusted hazard ratios of 0.56 (95% confi-
dence interval [CI]: 0.64 to 0.89; p  0.01) for all-cause mortality, 0.77 (95% CI: 0.67 to 0.89; p  0.01) for CV
events, and 0.68 (95% CI: 0.54 to 0.87; p  0.01) for AR events.
Conclusions This large retrospective study shows that the prescription of ACE inhibitors or ARBs in patients with moderate to
severe AR was associated with significantly reduced all-cause mortality and CV and AR events. These data need
to be confirmed by a prospective randomized controlled outcome trial. (J Am Coll Cardiol 2011;58:2084–91)
© 2011 by the American College of Cardiology Foundation
Published by Elsevier Inc. doi:10.1016/j.jacc.2011.07.043Chronic aortic regurgitation (AR) is a common valvular
heart disease and has been reported to occur in up to 10%
of the middle-aged to older population who undergo
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accepted July 26, 2011.echocardiography (1). The most common etiologies in-
clude aortic dilation, congenital bicuspid valves, and
hypertension. AR results in slow and insidious left
ventricular (LV) dilation, with a long asymptomatic
phase (2– 4). AR is important because approximately 6%
See page 2092
of patients with AR progress to symptoms of LV systolic
dysfunction (LVSD) or LV dilation each year, and the
mortality rate is approximately 10% per year in the
presence of LVSD (5).
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November 8, 2011:2084–91 ACE Inhibitors and ARBs in Aortic RegurgitationIn the early stages of AR, normal stroke volume is usually
maintained, because the left ventricle can respond well to
the increasing pressure and volume load created by the
incompetent valve (6). Increases in end-diastolic volume,
wall compliance, and LV hypertrophy occurring without
increases in filling pressures allow the left ventricle to
continue to maintain normal stroke volume (7). Progression
of AR results in increases in systolic wall stress, a combi-
nation of volume and pressure overload ensue, and this
increased LV afterload leads to further LV hypertrophy,
while still maintaining a normal stroke volume (8). It is in
this plateau phase, when the left ventricle is able to maintain
normal cardiac output because of enhanced LVH despite
increased afterload, that vasodilators are thought to have a
role (9,10). In short-term studies examining their effects,
vasodilators had been previously shown to reduce AR
volume (9,11) and improve LV hemodynamic parameters
(10–16). However, longer term studies have yielded con-
flicting results, and very few have assessed clinical outcomes
(15,17–19). The current American College of Cardiology
and American Heart Association 2006 guidelines recom-
mend the use of vasodilators only in patients with
hypertension with chronic, severe AR, with the goal of
reducing systolic blood pressure (20). Importantly the
guidelines do not recommend vasodilators as routine
therapy in the absence of systolic hypertension or in
asymptomatic patients with normal LV function. This
reflects the paucity of clinical data and the heterogeneity
of the findings of contemporary data. Importantly, there
has been no study of the impact of vasodilators on
survival.
In an animal model of chronic AR, Plante et al. (21)
demonstrated abnormal activation of the renin-angiotensin
system (RAS), which might suggest that blocking this
system could play an important role in preventing LV
dilation, hypertrophy, and loss of systolic function (21).
Recently, again using a rat model, the same investigators
showed that vasodilators targeting the RAS (captopril
and losartan) were more effective than nifedipine in
slowing the development of LV remodeling and preserv-
ing LV function (22). Because of the lack of evidence on
whether angiotensin-converting enzyme (ACE) inhibi-
tors improve survival in AR, we sought to investigate the
potential survival benefits of ACE inhibitors or angio-
tensin receptor blockers (ARBs) in a large retrospective
observational cohort of patients identified to have mod-
erate to severe AR by echocardiography.
Methods
Study design. This was a retrospective, population-based,
longitudinal cohort study. Data on all patients with new
diagnoses of AR were ascertained from a clinical echocar-
diographic database (110,000 scans) maintained by the
cardiology department at Ninewells Hospital (Tayside,
Scotland). These echocardiographic data were then linkedanonymously using a unique
patient-specific identifier, the
Community Health Index Num-
ber, to the Medicines Monitoring
Unit database of community-
dispensed prescriptions main-
tained by the Health Informatics
Centre at the University of Dun-
dee, which contains detailed pre-
scribing information on all res-
idents of Tayside (population
400,000) since 1993, as previ-
ously described (23). Other clinical
datasets included laboratory test
results, hospital admissions (Scot-
tish Morbidity Record), and mor-
tality data (General Registry Of-
fice). Access to the anonymized
and validated clinical datasets was
administered by the Health Infor-
matics Centre at the University of
Dundee using established proto-
cols approved by the Research
Ethics Committee in Tayside.
Study patients. All patients di-
agnosed with at least moderate AR were identified from the
echocardiographic database from September 1993 to July
2008. The diagnosis and severity of AR were ascertained by
British Society of Echocardiography–accredited sonogra-
phers at the time of the scan using approved techniques,
including jet dimensions within the LV outflow tract, the
direction of flow within the descending aorta, and pressure
half-time. Patients were entered into the study from the
date of the first echocardiographic study with a diagnosis of
AR and were censored when they underwent aortic valve
replacement (AVR), had a cardiovascular (CV) cause of
admission to the hospital, died, or left the region, as
appropriate. Patients with histories of malignancy were
excluded from the study. Patients in the ACE inhibitor or
ARB cohort (cases) were those who had 2 or more dis-
pensed prescriptions for ACE inhibitors or ARBs during
the follow-up period. All other patients who were never
prescribed ACE inhibitors or ARBs were analyzed as the
control cohort.
Outcomes. The primary outcome was defined as all-cause
mortality, with secondary outcomes of CV events (CV
death or hospitalization) and AR events (heart failure
hospitalization, heart failure death, or AVR). Hospitaliza-
tions were ascertained from the Scottish Morbidity Record
database; CV hospitalization was defined by primary Inter-
national Classification of Diseases-Ninth Revision (ICD-9)
codes (410, 411, 413, 428, and 430 to 438) and Interna-
tional Classification of Diseases-Tenth Revision (ICD-10)
codes (I20 to I22, I50, and I60 to I64) for myocardial
infarction, angina, heart failure, cerebrovascular accident,
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code I50. The main cause of death was ascertained from the
General Registry Office database, with CV death defined as
diseases of the circulatory system (ICD-9 codes 390 to 459
and ICD-10 codes I00 to I99) and heart failure death
defined as ICD-9 code 428 and ICD-10 code I50.
Statistical analyses. For comparison of baseline variables,
categorical data were analyzed using chi-square tests and
continuous variables using nonparametric Mann-Whitney
U tests. For the longitudinal outcome analysis, Kaplan-
Meier survival curves were generated, and the differences
between survival distributions were assessed using log-rank
tests. The effects of known prognostic clinical and echocar-
diographic variables were examined using Cox proportional
hazards regression analysis including age, sex, social depri-
vation category, LV function, LV dimension, diabetes, renal
function, CV history, and concurrent use of CV drugs as
covariates. We performed several sensitivity analyses. First,
to minimize confounding influences, we determined a
propensity score (a conditional probability of exposure to a
treatment given observed covariates) using a logistic regres-
sion model. We subsequently used the score to perform a
subgroup analysis in which cohorts of subjects exposed or
not exposed to ACE inhibitors or ARBs were matched for
propensity, with a tolerance of 0.05. Second, the association
between ACE inhibitor or ARB use and CV events was
assessed using a Cox regression model with a time-
Baseline CharacteristicsTable 1 Baseline Characteristics
Variable All No ACE Inhibit
n 2,266 1,390 (61.34%
Age (yrs) 74 (64–81) 75 (66–82)
Men 902 (40%) 526 (37.84%
BMI (kg/m2) 25 (23–29) 25.4 (23–29)
SBP (mm Hg) 142 (130–160) 140 (130–15
DBP (mm Hg) 73 (65–82) 75 (64–81)
Hemoglobin (mg/dl) 12.7 (11.6–14) 12.8 (11.4–1
Cholesterol (mmol/l) 4.90 (4.13–5.74) 4.88 (4.17–5
Creatinine (mmol/l) 98 (84–120) 97 (83–121
LVISD (cm) 3.03 2.58 2.88 2.54
Diabetes 298 (13%) 154 (11.07%
Renal admission 60 (3%) 35 (2.52%)
COPD 79 (3%) 50 (3.6%)
Previous event 625 (28%) 313 (22.52%
Aspirin 1,154 (51%) 594 (51.47%
Diuretic agents 545 (24%) 301 (21.6%)
Beta-blockers 789 (35%) 389 (27.98%
Calcium antagonists 774 (34%) 407 (29.28%
Digoxin 528 (23%) 283 (20.40%
Nitrates 705 (31%) 331 (23.81%
Statins 870 (38%) 369 (26.55%
LV impairment 1,030 (45%) 642 (46.18%
Values are n (%), median (interquartile range), or mean  SD.
ACE  angiotensin-converting enzyme; BMI  body mass index; COPD  chronic obstructive pu
ystolic diameter; SBP  systolic blood pressure.dependent variable for ACE inhibitor or ARB use. Third, sgiven the likely bias caused by the prescription of ACE
inhibitors to those with LVSD, we performed subgroup
analyses comparing patients with normal LV function and
those with LVSD and similarly in those with and without
dilated left ventricles on the basis of diastolic LV dimen-
sions. Additionally, we also performed subgroup analysis by
severity of AR in the subgroup of patients in whom blood
pressure data were available. All statistical analyses were
performed by skilled statisticians using SAS version 9.1
(SAS Institute Inc., Cary, North Carolina), and 2-sided p
values 0.05 were considered significant.
Results
Patient characteristics. A total of 2,266 patients with
moderate to severe AR were included in the study, with a
median age of 74 years (interquartile range: 64 to 81 years);
40% were men. Eight hundred seventy-six (39%) were
treated with ACE inhibitors. The baseline characteristics of
the population are shown in Table 1. Continuous variables
are presented as mean  SD or as medians (interquartile
ranges), while categorical variables are shown as percents.
Those treated with ACE inhibitors or ARBs were younger
(70 years vs. 72 years, p  0.01) and more likely to be male.
hey were also more likely to have LVSD, diabetes, or
revious CV events, and to be prescribed other CV medi-
ations. There was no significant difference in blood pres-
ACE Inhibitors
p Value
(ACE Inhibitors vs. No ACE Inhibitors)
876 (38.66%)
72 (63–79) 0.001
376 (42.9%) 0.02
26 (23–29) 0.87
140 (130–160) 0.68
75 (65–82) 0.71
13 (11.8–13.9) 0.001
4.9 (4.1–5.75) 0.73
99 (85–117) 0.98
3.28 2.62 0.001
144 (16.44%) 0.001
25 (2.85%) 0.63
29 (3.31%) 0.72
312 (35.62%) 0.001
560 (63.93%) 0.001
244 (27.90%) 0.001
400 (45.66%) 0.001
367 (40.96%) 0.001
245 (27.97%) 0.001
374 (42.69%) 0.001
501 (57.19%) 0.001
388 (44.29%) 0.38
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November 8, 2011:2084–91 ACE Inhibitors and ARBs in Aortic RegurgitationOutcomes. During a mean follow-up period of 4.4  3.7
years, there were 582 deaths (26%), 1,069 CV events (47%;
CV death or hospitalization), and 354 AR events (16%).
Sixty-five patients (2.7%) underwent AVR during follow-
up. Of the 876 patients (39%) who were treated with ACE
inhibitors or ARBs, 344 (39%) had CV events, 155 (18%)
had AR events, and all-cause mortality occurred in 127
(15%). Among patients not treated with ACE inhibitors or
ARBs, 725 (53%) had CV events, 199 (14%) had AR
events, and there were 455 deaths (33%). In the Cox
regression analysis, the adjusted hazard ratio (HR) associ-
ated with the use of ACE inhibitors or ARBs for CV events
was 0.77 (95% confidence interval [CI]: 0.67 to 0.89; p 
0.01). The adjusted HR associated with the use of ACE
inhibitors or ARBs for all-cause mortality was 0.56 (95%
CI: 0.46 to 0.68; p 0.001) (Table 2). The time-dependent
analysis showed similar findings, with adjusted HRs for CV
events and mortality of 0.45 (95% CI: 0.21 to 0.99) and 0.18
(95% CI: 0.06 to 0.54), respectively. Considering AR
events, the HR for those treated with ACE inhibitors or
ARBs was 0.68 (95% CI: 0.54 to 0.87; p  0.01) compared
ith those not treated. The Kaplan-Meier curves for all-
ause mortality, CV events, and AR events in patients with
ompared with those without ACE inhibitor or ARB
herapy are shown in Figure 1.
In the subgroup analysis based on LV dimensions,
atients with LV diastolic dimensions 6 cm had the
argest benefit with ACE inhibitor therapy: for LV diastolic
imension 6 cm, the HR was 0.77 (95% CI: 0.67 to 0.90;
 0.01), and for LV diastolic dimension 6 cm, the HR
as 0.52 (95% CI: 0.32 to 0.86; p  0.001) for all-cause
ortality. In patients with LVSD, the HRs for all-cause
ortality in those treated with ACE inhibitors or ARBs
ompared with those not treated were 0.56 (95% CI: 0.43 to
.74; p  0.001) for normal LV function, 0.28 (95% CI:
.17 to 0.47; p  0.01) for moderate LVSD, and 0.52 (95%
I: 0.27 to 1.0; p  0.04) for severe LVSD.
egree of regurgitation. We stratified outcome data on
he basis of the echocardiographers’ assessments of AR
everity. The beneficial effects on all-cause mortality of
CE inhibitor therapy were seen in patients with both
oderate and severe regurgitation, but the survival benefit
as most marked in the severe group (HR: 0.4; 95% CI:
.24 to 0.66; p  0.01), as shown in Table 3.
ropensity score–matched cohort analysis. To minimize
Study Outcomes With Adjusted HRsTable 2 Study Outcomes With Adjusted HRs
Outcome Event All Patients A
All-cause mortality 582 (26%)
CV events (CV death or hospitalization) 1,069 (47%)
AR events (HF hospitalization, HF death, or AVR) 354 (17%)
Values are n (%) unless otherwise indicated.
ACE angiotensin-converting enzyme; AR aortic regurgitation; ARB angiotensin receptor bl
R  hazard ratio.he potential bias inherent in post-discharge prescriptions of oCE inhibitors, and to address the effects of imbalanced
ovariants at baseline, we used a propensity score–matched
ohort analysis (24,25). The C statistic for the separation of
he groups in the regression model was 0.62. The cohort
onsisted of 1,702 patients, with 851 patients in each group
Table 4). The HRs in this analysis were 0.57 (95% CI: 0.41
o 0.79) for CV events, 0.73 (95% CI: 0.57 to 0.95; p 
.01) for AR events, and 0.39 (95% CI: 0.22 to 0.67; p 
.01) for all-cause mortality (Table 5).
iscussion
he medical management of patients with severe AR
emains controversial. Clinical trials focusing on AR are
are, with 2 studies that have examined the impact of
asodilators on clinical outcome in patients with chronic
R. Scognamiglio et al. (26) randomized 143 asymptomatic
atients with chronic, severe AR to either nifedipine or
igoxin. At the end of 6 years, patients treated with
ifedipine had a significantly lower rate of progression to
VR than those treated with digoxin. Post-operative LV
jection fractions after AVR were reported to be signifi-
antly higher in patients treated with nifedipine than with
igoxin. These findings contrast with those from a study by
vangelista et al. (19) that investigated the effect of enalapril
20 mg/day), nifedipine (20 mg), or no treatment in an
pen-label study involving 95 patients with asymptomatic
evere AR. After a mean follow-up period of 7 years, there
as no difference in any of the groups during follow-up in
he time to AVR, AR volume, or LV function on echocar-
iography. Considering these conflicting data and the pau-
ity of clinical data (a total of 238 patients enrolled), the
merican Heart Association and American College of
ardiology valvular heart disease treatment guidelines no
onger recommend any vasodilator for the medical manage-
ent of chronic AR in patients with normal ventricular
unction. Importantly, there has been no outcome study
nvestigating the impact of ACE inhibitors or vasodilators
n survival. In this study, we used a well-tested bioinfor-
atics platform with record linkage of an echocardiographic
atabase to prescribing and outcomes data (23) to identify a
otal of 2,266 subjects with moderate to severe AR and
xamined the impact of vasodilator therapy on outcome.
he mean follow-up period was 4.5 years. We have shown
hat in patients with AR, the prescription of ACE inhibitors
ibitors or ARBs No ACE Inhibitors or ARBs HR (95% CI)
27 (15%) 455 (33%) 0.56 (0.46–0.68)
44 (39%) 725 (52%) 0.77 (0.67–0.89)
55 (18%) 199 (14%) 0.74 (0.56–0.96)
VR aortic valve replacement; CI confidence interval; CV cardiovascular; HF heart failure;CE Inh
1
3
1r ARBs significantly reduced all-cause mortality, CV
2088 Elder et al. JACC Vol. 58, No. 20, 2011
ACE Inhibitors and ARBs in Aortic Regurgitation November 8, 2011:2084–91events, and AR events during the follow-up period com-
pared with patients not prescribed ACE inhibitors or
ARBs. Furthermore, subgroup analyses with respect to the
Figure 1 Events and Survival by
ACE Inhibitor or ARB Therapy
Kaplan-Meier curves illustrating the survival benefits in angiotensin-converting
enzyme (ACE) inhibitor or angiotensin receptor blocker (ARB) users (dotted lines),
compared with nonusers (solid lines), on (A) cardiovascular (CV) events (CV hospi-
talization or death), (B) all-cause mortality, and (C) aortic regurgitation (AR) events
(aortic valve replacement, heart failure hospitalization, or heart failure death).degree of AR, LV diastolic dimension, or the presence ofLVSD did not modify the overall results. To the best of our
knowledge, this is the largest retrospective observational
study showing the beneficial effects of ACE inhibitor or
ARB therapy in patients with at least moderate AR on
all-cause mortality and CV and AR events in “real world”
patients.
In our study, patients on ACE inhibitors or ARBs had a
higher incidence of significant comorbidities. It is likely that
the presence of diabetes, hypertension, and previous CV
events may have led to the prescription of ACE inhibitors or
ARBs. There were also differences in drug prescriptions in
the 2 groups; more patients in the ACE inhibitor group
were receiving CV medications in general, as shown in
Table 1. Arguably, all these differences at baseline would, if
anything, suggest that those treated with ACE inhibitors or
ARBs were actually at a much higher risk compared with
untreated patients. A higher rate of diuretic agent prescrip-
tion, for example, may suggest a higher prevalence of
symptoms of heart failure. Despite the probable higher CV
risk at baseline and the higher incidence of other comor-
bidities, we found that patients with AR who were treated
with ACE inhibitors or ARBs had better outcomes. This
observed difference in outcomes remained significant even
after accounting for confounding variables in both the Cox
regression model and the propensity score–matched cohort
analysis.
In this study, we were not able to specifically address the
potential effects of vasodilators such as dihydropyridine
calcium blockers, hydralazine, or nitrates because many of
these drugs are prescribed concomitantly with other agents,
such as calcium-channel blockers and nitrates, making it
difficult to determine the specific effects of vasodilators.
However, it should be noted that the choice of vasodilators
has been a subject of some debate. It has been argued that
vasodilators that block the RAS may be superior to other
vasodilators, such as dihydropyridine, calcium-channel
blockers, and hydralazine. In an animal model of chronic
AR, the RAS was abnormally activated, which might
suggest that blocking this system could play an important
role in preventing LV dilation, hypertrophy, and loss of
systolic function (21). Brain natriuretic peptide expression
was almost normalized by captopril and losartan but not by
nifedipine in a further study by the same group (22). Finally,
these 2 drugs that block the RAS were shown to decrease
the expression of fibrosis-related molecules such as collagens
I and III, lysyl oxidase, transforming growth factor beta-1,
transforming growth factor beta-2, and connective tissue
growth factor. All these findings would suggest that RAS-
targeting drugs have protective effects on the left ventricle
submitted to chronic volume overload before the occurrence
of systolic heart failure. With respect to clinical studies,
there have not been many head-to-head comparison studies.
Lin et al. (15) randomized 76 patients with chronic, mild to
severe AR to either enalapril or hydralazine. Both vasodi-
lators reduced LV mean wall stress at follow-up compared
with baseline, and comparisons between groups were non-
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November 8, 2011:2084–91 ACE Inhibitors and ARBs in Aortic Regurgitationsignificant. Neither vasodilator changed LV ejection frac-
tion significantly. However, enalapril significantly reduced
LV end-diastolic volume index, LV end-systolic volume
index, and LV mass index compared with hydralazine. In
another study, Banaszewski et al. (27) compared captopril
with nifedipine in 25 patients with chronic, moderate to
severe AR and showed that captopril but not nifedipine
reduced the grade of AR. The study by Evangelista et al.
(19) that investigated the effect of enalapril (20 mg/day),
nifedipine (20 mg), or no treatment in 95 patients with
asymptomatic severe AR found no difference in any of the
groups during follow-up in the time to AVR, AR volume,
or LV function on echocardiography. Similarly, a small
retrospective analysis of 18 pediatric cases failed to show a
benefit of ACE inhibitor therapy (28). To the best of our
knowledge, no studies have examined the structural or
hemodynamic effects of combined vasodilator therapy (i.e.,
ACE inhibitors and vasodilators) in patients with AR.
Current American College of Cardiology and American
Heart Association guidelines (20) recommend that ACE
Study Outcomes With Adjusted HRs for the Propensity Score–MatcTable 3 Study Outcomes With Adjusted HRs for the Propensity
Outcome Event All Patients
All-cause mortality 437 (26%)
CV events (CV death and hospitalization) 724 (43%)
AR events (CHF hospitalization or AVR) 287 (17%)
Values are n (%) unless otherwise indicated.
CHF  congestive heart failure; other abbreviations as in Table 3.
Baseline Characteristics for Propensity Score–Matched Cohort AnaTable 4 Baseline Characteristics for Propensity Score–Matche
Variable All No ACE Inhibit
n 1,702 851 (50%)
Age (yrs) 73 (63–80) 73 (62–81)
Men 716 (42%) 352 (41%)
BMI (kg/m2) 25 (23–29) 25 (23–29)
SBP (mm Hg) 142 (130–160) 140 (131–143
DBP (mm Hg) 73 (65–82) 75 (64–80)
Hemoglobin (mg/dl) 13 (11.7–14.1) 12.9 (11.4–14
Cholesterol (mmol/l) 4.9 (4.13–5.72) 4.9 (4.2–5.7)
Creatinine (mmol/l) 98 (85–119) 98 (85–121)
LVISD (cm) 3.28 (2.8–4.0) 3.27 (2.77–3.8
Diabetes 262 (15%) 129 (15%)
Renal admission 44 (2.6%) 19 (2%)
COPD 62 (4%) 34 (4%)
Previous event 582 (34%) 286 (34%)
Aspirin 918 (54%) 376 (44%)
Diuretic agents 442 (26%) 200 (24%)
Beta-blockers 636 (37%) 247 (29%)
Calcium antagonists 617 (36%) 261 (31%)
Digoxin 412 (24%) 175 (21%)
Nitrates 594 (35%) 235 (28%)
Statins 752 (44%) 264 (31%)
LV impairment 763 (45%) 381 (45%)Values are n (%) or median (interquartile range).
Abbreviations as in Table 1.inhibitor therapy in patients with AR be limited to the
hypertensive population, because the effects of high blood
pressure in AR serve to increase afterload (29). ACE
inhibitors are unlikely to directly reduce regurgitant volume,
because this is dependent on the fixed regurgitant orifice
area and the already reduced diastolic blood pressure (30).
CE inhibitors or ARBs may indeed deliver their beneficial
ffects purely by systolic blood pressure reduction, leading to
educed wall stress and improved LV systolic function (29).
e did examine the effect of ACE inhibitors or ARBs on
lood pressure and demonstrated no significant difference in
lood pressure for those with and without ACE inhibitor or
RB therapy at baseline. This raises the possibility that the
enefits of ACE inhibitors or ARBs may be independent of
he presence of systolic hypertension in patients with AR.
esides these proposed direct or indirect effects of ACE
nhibitors or ARBs on LV wall stress and remodeling, one
hould consider the possibility that the observed beneficial
ffects of ACE inhibitors or ARBs could simply be due to
heir general cardioprotective effects, as demonstrated in
Cohort Analysise–Matched Cohort Analysis
E Inhibitors No ACE Inhibitors HR (95% CI)
74 (20%) 263 (31%) 0.39 (0.22–0.67)
32 (39%) 392 (46%) 0.57 (0.41–0.79)
34 (16%) 144 (17%) 0.73 (0.57–0.95)
ort Analysis
ACE Inhibitors
p Value
(ACE Inhibitors vs. No ACE Inhibitors)
851 (50%)
72 (63–79) 0.18
364 (43%) 0.56
25 (22–29) 0.48
140 (130–152) 0.46
75 (65–80) 0.40
13 (11.8–14.1) 0.05
4.9 (4.1–5.8) 0.79
99 (85–117) 0.71
3.3 (2.8–4.1) 0.07
133 (16%) 0.78
25 (3%) 0.36
28 (3%) 0.44
296 (35%) 0.61
542 (63%) 0.01
242 (28%) 0.02
389 (46%) 0.01
356 (42%) 0.01
237 (27%) 0.01
359 (42%) 0.01
488 (57%) 0.01
382 (45%) 0.96hedScor
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(Heart Outcomes Prevention Evaluation) (31), SOLVD
(Studies of Left Ventricular Dysfunction) (32), SAVE
(Survival and Ventricular Enlargement) (33), and AIRE
(Acute Infarction Ramipril Efficacy) (34) studies. Obvi-
ously, any indication that the observed outcomes in our
study are due to the direct or indirect effects of ACE
inhibitor or ARB therapy on ventricular wall stress and
remodeling or a general cardioprotective effect is purely
speculative and cannot be inferred directly from this retro-
spective observational study.
Study limitations. We recognize the inherent limitations
that come with a retrospective, nonrandomized, observa-
tional study. However, the present study reflects the true
population and a real-world scenario and is unique in
comparison with other previous studies because of our large
number of patients with varying degrees of AR, but most
importantly because we found that ACE inhibitors or ARBs
reduce all-cause mortality and CV events in patients with
AR. We have also accounted for the baseline differences and
the influence of potential confounders by performing a
multivariate analysis for the outcome and a propensity
score–matched cohort analyses.
In common with all observational studies, it was impos-
sible for our study to account for unknown confounding
influences that may have biased the observed differences
between the groups considered. In particular, we had little
information regarding symptomatology, and one may sur-
mise that the patients receiving ACE inhibitors were more
likely to be symptomatic. However, symptoms are an
adverse prognostic sign in AR and would, if anything,
mitigate the benefit we saw with ACE inhibitors. Addi-
tionally, those treated with ACE inhibitors were slightly
younger (mean age 69.9 years vs. 72.0 years), making it
possible that these differences could have accounted for the
better outcomes observed in those who had been treated
with ACE inhibitors.
We recognize that our observed benefits of ACE
inhibitors or ARBs in relation to AR events were largely
driven by heart failure endpoints of heart failure hospi-
talization and death given the limited number of AVRs.
Another limitation is that the echocardiographic database
details overall assessment of severity of AR by accredited
sonographers as mild, moderate, or severe and does not
consistently report the measures of regurgitation directly.
This, combined with the lack of standardized echocar-
Adjusted HRs for the Impact ofCE Inhibitors ARBs on OutcomesStratified by the Severity of Regurgitation
Table 5
Adjusted HRs for the Impact of
ACE Inhibitors or ARBs on Outcomes
Stratified by the Severity of Regurgitation
Severity of AR n
All-Cause Mortality
HR (95% CI)
CV Events
HR (95% CI)
Moderate 1,803 0.58 (0.47–0.72) 0.79 (0.68–0.93)
Severe 463 0.4 (0.24–0.66) 0.70 (0.50–0.98)
Abbreviations as in Table 3.diographic follow-up data, limited our ability to reliablydetermine the effects of ACE inhibitor or ARB therapy
on the progression of aortic valve disease. Clearly, a large
randomized placebo-controlled trial would be required to
provide definitive evidence and further define the under-
lying mechanisms of the benefit of ACE inhibitors in
patients with AR.
Conclusions
These are the only retrospective outcome data on the use of
ACE inhibitor or ARB therapy in AR, and we have shown
that the prescription of ACE inhibitors or ARBs is associ-
ated with reduced all-cause mortality and CV and AR
outcomes in patients with moderate to severe AR. Our data
need to be confirmed by a prospective randomized con-
trolled outcome trial.
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